Supplementary methods

Inclusion criteria
Patients had to meet the following criteria for study entry: Interference with normal daily activities 9. Chest X-ray or computed tomography (CT) scan obtained within the 12 months prior to Visit 1 or chest X-ray during the screening period confirming the absence of other lung disease If a chest X-ray (or CT scan) within the 12 months preceding screening (Visit 1) is not available and a chest X-ray cannot be performed and reviewed prior to randomization (Visit 3), the patient will not be eligible for the study.
Demonstrated adherence with controller medication of ≥ 70% during the screening period
Adherence is defined as patients responding affirmatively that they have taken their asthma controller therapy ≥ 70% of days during the screening period (Visit 1 to Visit 3) as recorded in their peak flow / diary device.
Exclusion criteria
Patients who met any of the following criteria prior to randomization were excluded from study entry:
1. History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection 
Randomisation
Patients were randomised to the treatment arms through the interactive voice/web-based response system (IxRS) provided by Perceptive Informatics, Inc. The IxRS also assigned study treatment kits to patients at each visit during the placebo-controlled period. The placebo and active kits were filled and packaged to look identical.
Efficacy and safety assessments
Asthma exacerbations
At each study visit, the investigator asked directed questions to assess whether the patient had experienced any asthma exacerbations per protocol since the preceding visit. Given that exacerbations were the primary endpoint in this study, a dedicated eCRF was used to record information regarding protocol-defined exacerbation events.
Spirometry
Spirometric measures collected included FEV 1 , FVC (volume in litres) and PEF (litres per minute). The percentage of predicted FEV 1 and FVC was derived from these volume measurements using the equations derived from the National Health and Nutrition Examination Survey dataset as described by Hankinson and colleagues. [1] The acceptability of the data, including the graphic representations of the manoeuvres, was determined by blinded overreaders. Calculations for the reproducibility of the acceptable manoeuvres were programmed.
The last dose of a short-acting bronchodilator had to be at least 4 hours before testing, the last dose of a LABA at least 12 hours before testing, and the last dose of a LAMA at least 24 hours before testing. For patients who were not properly prepared for testing (e.g. had taken a bronchodilator before arrival), the visit was rescheduled.
Measurement of spirometry was performed on a computerised spirometry system, Vitalograph The AQLQ(S) was used to assess the patients' asthma-specific health-related quality of life. [3] The questionnaire contains four domains: activity limitations, symptoms, emotional function, and environmental stimuli. The AQLQ(S) has been validated for use in this study population. The AQLQ(S) has a recall specification of 2 weeks. The AQLQ(S) was administered to the patient prior to all other non-PRO assessments and before the patient received any disease-status information or study treatment during that assessment.
Asthma Control Questionnaire-5
Asthma control as measured by the ACQ-5 [4] was assessed by asking patients to recall their experiences during the previous week and to respond to five questions (i.e. night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheeze). The ACQ-5 had a recall period of 1 week. The items were scored on a scale between 0 (totally controlled) and 6 (extremely poorly controlled). The items were equally weighted, and the score was the mean of five items. During the placebo-controlled period, ACQ-5 was to be measured at baseline, Week 24, and treatment completion. However, given the median treatment duration of 24.1 weeks less than 50% of subjects contributed data for this endpoint.
Biomarker assessments
FeNO was assessed at baseline and at each subsequent study visit, using a hand-held portable device (NIOX MINO®, Aerocrine; Solna, Sweden) in accordance with the American Thoracic Society guidelines.
[5] Serum to evaluate periostin levels was collected at screening, baseline, and each subsequent study visit. Periostin was measured using the clinical trial version of the Roche Elecsys ® Periostin assay (Roche Diagnostics, Penzberg Germany) on the Cobas e601 platform, which is an electrochemiluminescence immunoassay, using the sandwich principle.
Patients, physicians and site staff were blinded to FeNO and periostin values during the study.
Haematological assessments, including peripheral blood eosinophil counts, were performed at screening, baseline, and at each subsequent study visit beginning at Week 4 using a central laboratory.
Efficacy analysis by baseline FeNO and blood eosinophil count
Efficacy data were also analysed by FeNO and blood eosinophil levels based on the median FeNO value at baseline (21 ppb) and the median blood eosinophil count at baseline (240 cells/µl).
Antibodies
A bridging immunoassay was used to first screen for and then confirm the presence of ATAs in patient samples. The level of response was measured by titering the confirmed positive samples. The same strategy was used in testing for antibodies to the host cell impurity PLBL2
PK assessments
Free lebrikizumab levels (PK) in serum were measured in quantitative immunoassays
Amended protocol
The placebo-controlled period was changed from 52 weeks to a range of 28-52 weeks. In the original protocol, all patients were to receive 13 doses of lebrikizumab or placebo during a 52 week period. With the amendment, all patients were to receive at least 7 doses of lebrikizumab or placebo during the 24 weeks of minimum-dosing visits. Patients were to continue to receive study drug treatment during the extended-dosing visits (for a maximum of 13 doses during a 48-week period) until the last patient in the study has received 7 doses. All patients were to have a treatment completion visit 4 weeks after completing their last dosing visit, thereby completing a 28-to 52-week placebo-controlled period.
Supplementary results
Exacerbations by trial
The distributions of the number of exacerbations by trial are shown in Table S1 . Lebrikizumab appeared to reduce exacerbations in both trials, although not in a dose-dependent manner.
There were a higher number of exacerbations in a few patients in the 250 mg lebrikizumab arm of the VERSE trial (8.3% with 2 exacerbations and 8.3% with 3 exacerbations in the periostinhigh subgroup and 7.1% with 2 exacerbations in the periostin-low subgroup) that were not apparent in the LUTE trial (3.4% with 2 exacerbations in the periostin-high subgroup).
Kaplan-Meier plots for the secondary endpoint 'time to first asthma exacerbation during the placebo-controlled period', are provided (see Figure S2 ). These plots show consistent findings to those from the primary analysis.
Secondary outcomes at Week 12
As shown in Table 4 there was evidence of increased time to first exacerbation with lebrikizumab treatment in periostin-high patients, especially in the 37.5 mg and 125 mg groups.
However, there was no indication of change in AQLQ(S) and no change in asthma rescue medication use. There was a trend towards a reduction in the rate of urgent asthma-related healthcare utilisation in periostin-high patients, particularly with 37.5 mg and 125 mg lebrikizumab.
Biomarkers
Figure 3 (main paper) shows the average FeNO value at each study visit through to Week 12
by treatment group in periostin-high and periostin-low patients. Baseline FeNO levels were lower in the placebo and lebrikizumab 37.5 mg groups, as well as in periostin-low patients ( fig.   3 ). The changes relative to placebo at Week 12 in periostin-high patients were -3.9 to -12.5 parts per billion (ppb) across the different lebrikizumab dose groups. At Week 12 in periostin-low patients the differences between the means in FeNO were -8.9 to -11.0 ppb across the lebrikizumab dose groups relative to placebo.
Baseline levels of peripheral blood eosinophils were well balanced across different treatment arms (table 1) . At Week 12 there was a small increase in absolute blood eosinophil levels with lebrikizumab, particularly in periostin-high subjects. The placebo-corrected change ranged from 0.29 to 0.56 x10
Baseline levels of serum periostin were also well balanced across different treatment arms ( fig. 3 ). Supplement figure S3 shows the biomarker data as mean change from baseline.
Efficacy data by baseline FeNO and blood eosinophil measurement
Asthma exacerbations
As for periostin, the exacerbation rate reduction compared with placebo was more pronounced in FeNO-high (≥ 21 ppb) and eosinophil-high patients (≥ 240 cells/µl) than in respective FeNOlow (< 21 ppb) and eosinophil-low patients (< 240 cells/µl) (table S3). In FeNO-high patients there was a 48% reduction in the rate of exacerbations for the lebrikizumab dose groups combined compared with placebo. In the FeNO-low patients, a 27% reduction was observed (table S3) . In eosinophil-high patients there was a 39% reduction in the rate of exacerbations for the lebrikizumab dose groups combined compared with placebo. In the eosinophil-low patients, a 19% reduction was observed.
Lung function
Similarly, for relative change in FEV 1 from baseline to Week 12 there was 7.2% improvement with lebrikizumab compared with placebo in FeNO-high patients and 2.0% in FeNO-low patients, and an 8.7% improvement with lebrikizumab compared with placebo in eosinophil-high patients and 2.6% in eosinophil-low patients (table S3) .
Anti-therapeutic antibodies and anti-PLBL2
Of the 347 lebrikizumab-treated patients, 329 had adequate samples for ATA evaluation (i.e.
pre-treatment as well as an appropriately timed post-treatment sample). A total of 26 patients tested positive for ATA after receiving study drug (plus one patient in the placebo group). This included 12 (10%) patients in the lebrikizumab 37.5 mg, 7 (6%) patients in the lebrikizumab 125 mg, and 7 (6%) in the lebrikizumab 250 mg groups. A total of 6 patients, all in the lebrikizumab arms (2% of total) were positive at baseline (three patients in the 37.5 mg group, two patients in the 125 mg group and one patient in the 250 mg group). Fifteen of the positive patients were considered to be transiently positive (duration of response lasting less than 16 weeks), while the remaining 11 patients were considered to be persistently positive. Onset of the positive response was by Week 12 in nearly all cases.
Two of these patients (one patient in the 125 mg group and one patient in the 250 mg group)
showed potential impact of ATA on their pharmacokinetic profiles. However, no clear evidence of the effect of ATA development on efficacy and PD biomarkers was observed. No apparent differences in safety were evident when comparing data from these patients with data from other similarly treated patients. There was no correlation between ATA status and injection site reactions or any hypersensitivity or immunological events. There was dose-dependent correlation with ATA detection.
A process-related Chinese hamster ovary CHO-derived protein impurity was identified in the lebrikizumab clinical trial material used in this study. This material has been identified as CHO PLBL2.
Samples were tested for the presence of anti-PLBL2 antibodies at the same time points as ATA ( Table S4 ). The clinical significance of anti-PLBL2 antibodies is not known. No clinically important safety signals were identified in this study and no correlation between safety events could be made.
Safety
Twelve serious AEs were reported in nine patients during the placebo-controlled part of the study: two patients in the placebo group (umbilical hernia, muscle strain), three patients in the lebrikizumab 125 mg group (intervertebral disc protrusion, gonococcal arthritis, organ donation, anaemia, rectal haemorrhage) and four patients in the lebrikizumab 250 mg group (back pain, chest pain, syncope, fractured coccyx, pleural effusion [presentation of non-Hodgkin's lymphoma noted below]).
The events leading to study drug withdrawal included two cases of asthma and one case of hypersensitivity in the placebo group, one injection site rash in the lebrikizumab 37.5 mg group, one case each of cough, rash and injection site pruritus in the lebrikizumab 125 mg group and one case each of injection site reaction, hypersensitivity, pleural effusion and fibromyalgia in the lebrikizumab 250 mg group.
Five neoplasms (capturing benign, malignant and unspecified neoplasms including cysts and polyps) were reported during the study, none of which were considered related to study drug; placebo group: skin papilloma, lebrikizumab 37.5 mg group: stage I breast cancer, lebrikizumab 125 mg group: a uterine leiomyoma, and lebrikizumab 250 mg group: non-Hodgkin's lymphoma and an intraductal proliferative breast lesion. In addition, a benign pituitary tumour was reported in the lebrikizumab 37.5 mg group. 
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